Nasdaq: CLYM
Climb Bio, Inc. (CLYM)
Climb Bio, Inc. is a public company that reports to the U.S. Securities and Exchange Commission and trades on Nasdaq under the ticker CLYM. Bright Analyst brings its financial statements, SEC filings, stock performance, news and peer comparisons together in one place, with AI analysis throughout.
Key facts
- Ticker symbol
- CLYM
- Exchange
- Nasdaq
- SEC CIK
- 1768446
- Official filings
- SEC EDGAR
Research CLYM
- Profile — Business description, headquarters, subsidiaries and corporate identifiers.
- Financials — Income statement, balance sheet and cash flow from 10-K and 10-Q filings.
- SEC Filings — Every 10-K, 10-Q and 8-K, readable inline with AI analysis.
- Stock Analysis — Price chart, returns, technical indicators and related companies.
- News — Latest headlines and press coverage.
- Material Contracts — Material agreements filed as exhibits to SEC reports.
- Benchmark — Stock performance against the S&P 500, Nasdaq-100 and Dow (through SPY, QQQ and DIA) and economic indicators.
- Peer Comparison — Side-by-side financial ratios against industry peers.
Frequently asked questions
What is Climb Bio, Inc.'s stock ticker?
Climb Bio, Inc. trades under the ticker symbol CLYM on Nasdaq. Its SEC Central Index Key (CIK) is 1768446.
Where can I read Climb Bio, Inc.'s SEC filings?
The CLYM SEC Filings page lists the 10-K annual reports, 10-Q quarterly reports and 8-K current reports Climb Bio, Inc. has filed, with AI analysis. The original documents are also on SEC EDGAR.
How can I analyze CLYM's financial statements?
The CLYM Financials page shows Climb Bio, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly, taken from its XBRL filings, with an AI analysis of each statement.
How does CLYM compare with its peers and the market?
The CLYM Peer Comparison page lines Climb Bio, Inc. up against industry peers on valuation, growth and profitability ratios, and the Benchmark page compares its stock with the S&P 500, the Nasdaq-100 and the Dow.
For information only — not investment advice.